Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.
Journal: Neurology
Published: November 17, 2025
Recommended approaches to sharing individual research results in Alzheimer's disease research: A multidisciplinary expert Delphi consensus.
Journal: Journal of Alzheimer's disease : JAD
Published: September 25, 2025
Early Alzheimer's disease patient care pathway and health system readiness: A framework for integrated care.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: June 24, 2025
Building expert consensus regarding sharing of individual research results in Alzheimer's disease research: a Delphi study protocol.
Journal: BMJ open
Published: August 24, 2024
Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis.
Journal: PLoS medicine
Published: July 17, 2024
The Skin and Lewy Body Disease.
Journal: Journal of Alzheimer's disease : JAD
Published: July 05, 2024
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: February 05, 2024
Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: May 04, 2023
Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.
Journal: Drugs & aging
Published: April 25, 2022
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies.
Journal: Neurology and therapy
Published: July 27, 2021
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
Journal: Drug design, development and therapy
Published: January 09, 2021
An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB).
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: November 23, 2020
Last Updated: 09/26/2026